Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 4/20 | 0.41 |
| ▸ | MMP9 | P14780 | 3/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | CASP7 | P55210 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13792676 | 1.00 | LMNA (0.43) | LMNAALDH1A1PKMSMN1; SMN2MAPT | |
| SCHEMBL3987812 | 0.86 | LMNA (0.45) | LMNAALDH1A1SMN1; SMN2MAPTCASP3 | |
| SCHEMBL6592289 | 0.85 | ATM (0.41) | LMNAALDH1A1SMN1; SMN2MAPTMMP1 | |
| SCHEMBL3987303 | 0.85 | KCNA5 (0.40) | LMNAALDH1A1PKMSMN1; SMN2MAPT | |
| SCHEMBL3990845 | 0.84 | KCNA5 (0.42) | LMNAALDH1A1PKMSMN1; SMN2MAPT | |
| SCHEMBL3996224 | 0.81 | DRD2 (0.37) | LMNAALDH1A1PKMSMN1; SMN2CASP3 | |
| SCHEMBL26103002 | 0.80 | GRM2 (0.51) | LMNAALDH1A1PKMSMN1; SMN2MMP1 | |
| SCHEMBL13792417 | 0.79 | CASP3 (0.40) | ALDH1A1PKMCASP3CASP7 | |
| SCHEMBL3991453 | 0.78 | SIGMAR1 (0.51) | LMNAALDH1A1PKMMMP1MMP13 | |
| SCHEMBL15757876 | 0.73 | GRM2 (0.53) | LMNAALDH1A1PKMSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544812-B2 | For example, 2-(4-{2-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-ethoxy}-2-methyl-phenoxy)-2-methyl-propionic acid, 2-(4-{3-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-propyl}-2-methyl-phenoky)-2-methyl-propionic acid; for treating diabetes mellitus | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544812-B2 | For example, 2-(4-{2-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-ethoxy}-2-methyl-phenoxy)-2-methyl-propionic acid, 2-(4-{3-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-propyl}-2-methyl-phenoky)-2-methyl-propionic acid; for treating diabetes mellitus | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544812-B2 | For example, 2-(4-{2-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-ethoxy}-2-methyl-phenoxy)-2-methyl-propionic acid, 2-(4-{3-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-propyl}-2-methyl-phenoky)-2-methyl-propionic acid; for treating diabetes mellitus | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-20050020652-A1 | Peroxisome proliferator activated receptor agonists | ELI LILLY AND COMPANY | 2005-01-27 | — | — | US | disclosed |
| EP-1453811-A2 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003048130-A2 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020652-A1 | Peroxisome proliferator activated receptor agonists | PPARA, PPARD, PPARG | LMNA 2723/4885ALDH1A1 1294/4885PKM 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.